PDF 240kWORD 47k

pursuant to Rule 133 of the Rules of Procedure

on an effective treatment for Alzheimer’s disease

Mireille D’Ornano

Motion for a European Parliament resolution on an effective treatment for Alzheimer’s disease  

The European Parliament,

–  having regard to Article 168 of the Treaty on the Functioning of the European Union,

–  having regard to Rule 133 of its Rules of Procedure,

A.  whereas, according to the World Health Organisation, 36 million people worldwide have dementia (2010), most of whom suffer from Alzheimer’s disease;

B.  whereas, according to a study published on 31 August 2016, the ‘aducanumab’ preventative treatment, which targets beta-amyloid and was developed by Biogen, proved partially effective in the phase I clinical trials carried out on 165 participants, but whereas before now, potential treatments for Alzheimer’s disease that target beta-amyloid have either proved ineffective or caused serious side effects;

C.  whereas a study published on 9 December 2016 (The Lancet), which was conducted by Sweden’s Karolinska Institute and consisted of a phase I clinical trial in which 30 patients were administered a vaccine that targets the tau protein, concluded that the vaccine is likely to prove effective, and whereas other vaccines and treatments are being developed;

1.  Urges the Commission to support European research into a treatment, and especially a vaccine, for Alzheimer’s disease, and innovative therapeutic treatments such as those mentioned in recital C.

Legal notice - Privacy policy